There are no data regarding management and outcomes of major bleeding events in patients treated with oral factor Xa inhibitors.
Introduction
There is limited information on the management of bleeding events in patients treated with factor Xa inhibitors. Additionally, there is uncertainty about the extent to which generic approaches to bleeding management or specialized coagulation products are required in such patients. In the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), rivaroxaban was shown to be non-inferior to warfarin for the prevention of stroke and systemic embolism, with less intracranial and fatal bleeding. 1 Novel agents, including rivaroxaban, have several advantages, including shorter half-lives, more rapid clearance from the circulation, and fewer drug-drug interactions compared with vitamin K antagonists (VKA). Nevertheless, questions remain about the management and outcomes of major bleeding events in patients treated with factor Xa inhibitors. Among the concerns expressed by clinicians is whether or not specific 'reversal' agents or specialized blood coagulation products may be needed to manage patients following major bleeding. 2 The goal of this analysis is to describe the management and outcomes of major bleeding in the ROCKET AF trial. Further, we sought to determine whether management and subsequent outcomes differed between those treated with rivaroxaban vs. warfarin.
Methods
The rationale and design of the ROCKET AF trial has been previously reported. 3 ROCKET AF was a multicentre, international, double-blind, double-dummy, event-driven, non-inferiority trial designed to compare the efficacy and safety of rivaroxaban vs. warfarin in patients with nonvalvular AF. ROCKET AF randomized 14 264 patients at 1178 sites with AF at moderate-to-high risk for stroke. Patients were required to have a history of stroke, transient ischaemic attack (TIA) or systemic embolism, or at least two of the following: heart failure or a left ventricular ejection fraction ≤35%, hypertension, age ≥75 years, or diabetes mellitus. Furthermore, the proportion of patients who had not had a previous ischaemic stroke, TIA, or systemic embolism, and who had no more than two risk factors was limited to 10% of the cohort for each region; the remainder of patients was required to have prior TIA, stroke, or systemic embolism or more than two risk factors. Exclusion criteria included: active internal bleeding, conditions predisposing to increased bleeding risk (e.g. major surgical procedure or trauma ≤30 days; clinically significant gastrointestinal bleeding ≤6 months; history of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding; bleeding diathesis; known intracranial neoplasm, arteriovenous malformation, or aneurysm; platelet count ,90 000/mL at the screening visit; sustained uncontrolled hypertension), aspirin .100 mg daily or aspirin in combination with thienopyridines, anticipated need for chronic treatment with a non-steroidal anti-inflammatory drug, anaemia (haemoglobin ,10 g/dL) at the screening visit, calculated creatinine clearance ,30 mL/min at the screening visit, significant liver disease (e.g. acute clinical hepatitis, chronic active hepatitis, cirrhosis), or alanine aminotransferase greater than three times the upper limit of normal.
Patients were randomized to receive rivaroxaban 20 mg daily (or 15 mg daily in patients with a creatinine clearance of 30 -49 mL/min) or adjusted-dose warfarin [target international normalized ratio (INR), 2.0 -3.0]. A point-of-care device was used to generate encrypted values that were sent to an independent study monitor, who provided sites with either real INR values (for patients in the warfarin group in order to adjust the dose) or sham values (for patients in the rivaroxaban group receiving placebo warfarin). All patients provided written informed consent.
Study population
The analysed population was the on-treatment (or 'safety') population: patients who received at least 1 dose of study drug. The analysis excludes 50 patients from 1 Good Clinical Practice-violating site. Sites and investigators were instructed to manage major bleeding events with cessation of study medication, discontinuation of antiplatelet drugs, and empiric administration of vitamin K or FFP when needed. Sites were advised that factor concentrates might be helpful in cases of major or life-threatening bleeding refractory to FFP.
Event and endpoint definitions
The clinical event of interest was major bleeding defined as clinically overt bleeding associated with any of the following: fatal outcome, involvement of a critical anatomic site (intracranial, spinal, ocular, pericardial, articular, retroperitoneal, or intramuscular with compartment syndrome), fall in haemoglobin concentration .2 g/dL, transfusion of .2 units of whole blood or packed red blood cells (PRBC), or permanent disability. 4 A clinical events committee was blinded to treatment assignment and adjudicated all bleeding events using the primary source data and documents. The committee adjudicated both the anatomic site and severity of the bleed using the International Society on Thrombosis and Haemostasis (ISTH) criteria. 4 Efficacy endpoints were considered from randomization until site notification and included all-cause death, stroke, or non-central nervous system (CNS) embolism, myocardial infarction, and surgical intervention for bleeding (e.g. haematoma evacuation, fasciotomy, or surgery for correction of haemorrhage). Safety outcomes were measured during the safety period (from first drug dose to last dose +2 days), unless specified otherwise. Safety outcomes included the duration of hospitalization and transfusion, including all products and factors.
Statistical methods
Baseline characteristics are presented as median (25th, 75th percentiles) for continuous variables and as percent (number) for categorical variables, and are summarized by treatment for subjects who experienced at least one major bleed and for those that did not have any major bleed. A subject could have experienced more than one major bleed; hence, information from all bleeds in the study was used to summarize location of major bleeds, duration of hospitalization, transfusion information after a major bleed, and pharmacologic management after a major bleed by treatment.
A generalized estimating equation (GEE) logistic regression model was utilized to find the important predictors of receipt of FFP or cryoprecipitate transfusions following a major bleed. Candidate covariates included randomized treatment, sex, race, prior aspirin, prior VKA, prior stroke/ TIA, history of heart failure, diabetes, hypertension, age, body mass index, creatinine clearance, and days to major bleed. Model selection was performed using stepwise selection with P ¼ 0.05 as entry and removal criteria.
Outcomes occurring after major bleed were summarized as rates and time to the outcomes were summarized as median (25th, 75th percentiles), with the date of major bleed being day 1. Hazard ratios for randomized treatment were estimated using adjusted proportional hazards model for the outcome of interest where major bleed was included as a time-dependent covariate. In addition to major bleed, the models included treatment, treatment by major bleed interaction, sex, history of chronic obstructive pulmonary disease, history of stroke or TIA, history of peripheral arterial disease, atrial fibrillation type, history of heart failure, region, history of alcohol use, age, diastolic blood pressure, systolic blood pressure, heart rate, body mass index, creatinine clearance, and interactions of each of these covariates with treatment.
All analyses were performed using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results

Baseline characteristics
Among the 14 143 randomized patients in this analysis (n ¼ 50 excluded from the GCP violating site), 779 experienced major bleeding (5.5%), 57 experienced 2 major bleeds (0.4%), and 2 patients had more than 2 bleeds (0.01%). Figure 1 illustrates the time to major bleeding according to the randomized treatment. The major bleeding rate was 3.52 events per 100 patient-years. Among 779 bleeding events, 775 (99.5%) occurred while patients were taking the assigned study medication. The baseline characteristics of patients with bleeding events stratified by both the classification of the bleeding event and the treatment assignment are shown in Table 1 . The median CHADS 2 score was 3 (25th, 75th: 3, 4) in those patients who experienced a major bleed and those who did not. HAS-BLED scores were similar in those with and without major bleeding [3 (3, 4) vs. 3 (3, 4) ]. The baseline characteristics of those patients with a major bleeding event, including creatinine clearance, were similar in those randomized to rivaroxaban and warfarin, except those patients with a major bleed on rivaroxaban were less frequently Asian (11.2 vs. 18.3%) and more frequently white (84.3 vs. 78.1%) compared with those on warfarin.
Location of major bleeding
The distribution of multiple bleeds and the location of major bleeding events are shown in Table 2 . The occurrence of two or more major bleed events was infrequent in the rivaroxaban and warfarin patients (0.5 vs. 0.0%). Major bleeding in the rivaroxaban arm was more frequently located in the upper gastrointestinal tract (38.1 vs. 25.7%), less commonly intracranial (12.8 vs. 20.5%), and less commonly intraocular or retinal (4.4 vs. 6.6%). 
Transfusion and hospitalization
Transfusion and hospitalization after major bleeding data are provided in Table 4) .
Unblinding
Throughout the course of the trial, 25 patients (0.017%) required unblinding of their treatment drug assignment. Three patients in the rivaroxaban group were unblinded within a day of the major bleed and five patients in the warfarin group were unblinded within 2 days of the major bleed. There was a single major bleeding event in the rivaroxaban group with an unblinding date preceding the bleed date. rivaroxaban arm vs. the warfarin arm (6.5 vs. 8.5%). Prothrombin complex concentrates were administered less frequently in the rivaroxaban arm [n ¼ 4 (0.9%) vs. n ¼ 9 (2.2%)]. Few patients received recombinant factor VIIa, factor VIII, or factor IX within 1 day of major bleeding in either treatment arm (rivaroxaban n ¼ 1, warfarin n ¼ 5). Results were similar when considering larger treatment windows within 2 and 3 -5 days of major bleeding ( Table 5 ).
Pharmacologic management
Outcomes following a major bleeding event
Outcomes following a major bleeding event, the interaction tests for randomized treatment and major bleeding, and the HR (95% CI) for the outcomes in the adjusted model before and after major bleeding events are shown in Table 6 . Event rates were similar in the rivaroxaban and warfarin arms for stroke or non-CNS embolism, myocardial infarction/unstable angina, and the composite of all stroke, non-CNS embolism, myocardial infarction/unstable angina, and all-cause death. Similarly, once a major bleed had occurred, all-cause death after bleeding was similar in the rivaroxaban arm compared with warfarin (20.4 vs. 26.1%; interaction P ¼ 0.1098).
Discussion
Novel oral anticoagulants are attractive alternatives to warfarin; however, concerns exist regarding treatment of major bleeding events in patients taking these agents. In our analysis of patient management following the 779 major bleeding events overall, there are several important clinically relevant findings. First, transfusion of coagulation factors was rare in both warfarin and rivaroxaban patients and the patients were largely managed using supportive approaches to bleeding. Second, transfusion of FFP was significantly more frequent in warfarin patients. Finally, major adverse outcomes, including death, following a major bleeding event were similar in patients treated with rivaroxaban and warfarin. Therefore, despite concerns about a 'lack of reversibility' for factor Xa inhibitors, outcomes following a major bleed are similar to those of VKAs. Factor Xa inhibitors offer several advantages compared with VKAs, including rapid onset of anticoagulation, shorter half-lives, and predictable pharmacokinetics without the need for routine monitoring. The ROCKET AF trial demonstrated that the factor Xa inhibitor rivaroxaban was non-inferior to warfarin for the prevention of stroke and non-CNS embolism in patients with non-valvular AF with a lower risk of intracranial and fatal bleeding. Despite these findings, many physicians express concern about the ability to manage major haemorrhage in these patients due to the lack of an easily administered, Xa-specific reversal strategy. More precisely, there are concerns that major haemorrhage in patients treated with factor Xa inhibitors could be uncorrectable, leading to fatal haemorrhage. In contrast, warfarin has several potential reversal agents, although their efficacy and time to effective reversal are suboptimal. Full reversal of warfarin with vitamin K can take more than 24 h and has questionable efficacy 5 and infusion of FFP can take several hours, requires large volumes, and necessitates repeated dosing for full reversal. 6 As a result, life-threatening warfarin-associated bleeding is preferably managed with PCC. 7 Early studies with healthy volunteers suggest that PCC may also have the potential to reverse the anticoagulant effects in those treated with factor Xa inhibitors. 8 However, these agents must also be used cautiously since they carry risk of prothrombotic effects. In this context, there are several important and reassuring findings in this analysis of management and outcomes of major bleeding events in patients treated with rivaroxaban or warfarin. 9, 10 The most important of these findings is that transfusion of coagulation factors was very rare in both warfarin and rivaroxaban patients and the patients were successfully managed using general, supportive approaches to bleeding. In the ROCKET AF trial, investigators were instructed to manage major bleeding with cessation of the anticoagulation study drug and empiric administration of vitamin K and FFP if life-threatening bleeding continued. that coagulation factor administration could be considered in patients with refractory bleeding despite infusion of fresh frozen plasma. In 14 143 patients, 779 experienced a major bleed and only 19 cases were treated with coagulation factor administration, including only five in the rivaroxaban-treated patients. These data complement the findings in the overall ROCKET AF trial, which demonstrated a lower risk of intracranial and fatal bleeding in those patients randomized to rivaroxaban. 1 Not only is fatal bleeding less likely, administration of haemostatic products was minimal. In this study of management for major bleeding, we also found that patients randomized to rivaroxaban received FFP less frequently. Following adjustment for prior aspirin use, VKA use, and previous stroke or TIA, we found that patients treated with rivaroxaban were significantly less likely to receive FFP. Patients with prior exposure to aspirin and VKAs were more likely to receive FFP. Studies in healthy human subjects suggest that four-component PCC can reverse the anticoagulant effect of rivaroxaban. 8 These data raise the question of whether the factor Xa inhibition can be overcome with FFP administration. It is important to emphasize that the ROCKET AF trial experience does not provide data that FFP reverses the anticoagulant effects of rivaroxaban in patients with haemorrhage. However, these observations do provide some reassurance that major bleeding in rivaroxaban does not require empiric administration of reversal transfusions more than warfarintreated patients. Finally, it is important to note that FFP transfusion rates were low overall. Although physicians may express a desire for specific 'reversal agents,' these interventions are not used in the vast majority of bleed events. The third and most important finding in this analysis is that there is no evidence of worse outcomes following major bleeding events in patients treated with rivaroxaban. Specifically, there was no evidence of an interaction between randomized treatment (rivaroxaban or warfarin) and major bleeding for stroke or non-CNS embolism or myocardial infarction/unstable angina, or all-cause death. In fact, the event rates in the rivaroxaban patients for stroke or non-CNS embolism and the composite endpoint were numerically lower in the rivaroxaban groups. Furthermore, the duration of hospitalization following a major bleeding event was shorter in the rivaroxabantreated patients. Following a major bleeding event, the hazard of death was 0.688 (95% CI 0.455, 1.042) for rivaroxaban compared with warfarin. While the interaction term did not reach statistical significance (P ¼ 0.1098), the lower mortality is very similar to data observed in patients treated with dabigatran (pooled odds ratio 0.68; 95% CI , 0.46-1.01; P ¼ 0.057).
11 These data also confirm and extend the safety findings observed in the ROCKET AF trial where fatal bleeding was less common in patients treated with rivaroxaban compared with warfarin and there was no evidence of worse outcomes in patients treated with rivaroxaban once a major bleeding event occurred.
Limitations
As with any post hoc analysis, there are several limitations that must be kept in mind when considering these data. First, bleeding events are post-randomization events and the comparison between patients taking rivaroxaban and warfarin may be subject to residual confounding. Second, these results may not be applicable to all major bleeding events, particularly acute traumatic events such as traumatic limb loss. Finally, patients presenting for emergency medical care in the setting of haemorrhage may have had unblinded INR assessment, which may have disclosed or biased the treating physician to assume knowledge of the randomized therapy.
Conclusions
Among high-risk patients with atrial fibrillation who experienced major bleeding in ROCKET AF, the use of FFP and PCC was less among those allocated rivaroxaban compared with warfarin. However, use of PRBC and outcomes after bleeding were similar among patients randomized to rivaroxaban or to warfarin.
